Advances in pharmaceutic managements of migraine

doi:10.3969/j.issn.1672-6731.2022.02.008

Abstract

Abstract: Migraine is a neurovascular disorder with great burden so that effective abortive and preventive treatment is needed. Different from the previous choice of drugs based on clinical experience, the specific treatment targeting the pathogenesis of migraine has revolutionized the management of migraine in recent years. Ditans and gepants can not only effectively relief headache and related symptoms but also be effective for those who are refractory to the abortive treatment by traditional painkillers or triptans. A variety of monoclonal antibodies against calcitonin gene-related peptide (CGRP) and CGRP receptor can effectively reduce headache attacks, especially when accompanied by other difficult clinical situations. This paper reviews the research progress of migraine drugs and its impact on clinical practice.

Key words: Migraine, Drug therapy, Calcitonin gene-related peptide, Antibodies, monoclonal, Review

摘要： 偏头痛是疾病负担极其严重的神经血管性疾病，需予以有效的急性期和预防性治疗。不同于既往仅依据临床经验选择药物，近年以偏头痛发病机制为靶点的特异性治疗给偏头痛的管理带来革命。地坦类和吉泮类药物可以有效减少头痛及其他相关症状，亦对传统镇痛药或曲坦类药物治疗无效者有效。多种降钙素基因相关肽及其受体单克隆抗体可以有效减少头痛发作，尤其是临床难以处理的伴发焦虑和抑郁障碍、药物过度使用性头痛或多种传统预防性药物治疗失败的患者。本文综述偏头痛药物研究进展及其对临床实践的影响。

关键词: 偏头痛, 药物疗法, 降钙素基因相关肽, 抗体,单克隆, 综述

LI Yan-sheng. Advances in pharmaceutic managements of migraine[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(2): 104-109.

李焰生. 偏头痛药物治疗进展[J]. 中国现代神经疾病杂志, 2022, 22(2): 104-109.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2022.02.008

https://journal11.magtechjournal.com/cjcnn/EN/Y2022/V22/I2/104

References

[1] Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB. Migraine:epidemiology and systems of care[J]. Lancet, 2021, 397:1485-1495.
[2] Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M, Steiner T. The prevalence and burden of primary headaches in China:a population-based door-to-door survey[J]. Headache, 2012, 52:582-591.
[3] Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden:the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women:findings from GBD2019[J]. J Headache Pain, 2020, 21:137.
[4] Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW. Migraine:integrated approaches to clinical management and emerging treatments[J]. Lancet, 2021, 397:1505-1518.
[5] Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults:fourth edition[J]. Cephalalgia, 2019, 39:687-710.
[6] Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine:a randomised, phase 3, double-blind, placebo-controlled trial[J]. Lancet, 2019, 394:737-745.
[7] Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine[J]. N Engl J Med, 2019, 381:142-149.
[8] Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the treatment of migraine[J]. N Engl J Med, 2019, 381:2230-2241.
[9] Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine:the ACHIEVE Ⅱ randomized clinical trial[J]. JAMA, 2019, 322:1887-1898.
[10] Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM. Long-term safety evaluation of ubrogepant for the acute treatment of migraine:phase 3, randomized, 52-week extension trial[J]. Headache, 2020, 60:141-152.
[11] American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice[J]. Headache, 2019, 59:1-18.
[12] Negro A, Martelletti P. Gepants for the treatment of migraine[J]. Expert Opin Investig Drugs, 2019, 28:555-567.
[13] Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine[J]. Brain, 2019, 142:1894-1904.
[14] Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine:a phase 3 randomized study[J]. Neurology, 2018, 91:e2222-2232.
[15] Brandes JL, Klise S, Krege JH, Case M, Kudrow D. Long-term safety and efficacy of lasmiditan for acute treatment of migraine:final results of the GLADIATOR study[J]. Cephalalgia Reports, 2020, 3:251581632095817.
[16] Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition):on behalf of the European Headache Federation and Lifting The Burden:the Global Campaign against Headache[J]. J Headache Pain, 2019, 20:57.
[17] Lipton RB, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M, Coric V, Croop R. Long-term, open-label safety study of rimegepant 75 mg for the treatment of migraine (Study 201):interim analysis of safety and exploratory efficacy (IHC-PO-127)[J]. Cephalalgia, 2019, 39(suppl):1-337.
[18] Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine:a phase 2/3, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2021, 397:51-60.
[19] Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan F, Trugman JM; ADVANCE Study Group. Atogepant for the preventive treatment of migraine[J]. N Engl J Med, 2021, 385:695-706.
[20] Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J. Eptinezumab in episodic migraine:a randomized, double-blind, placebo-controlled study (PROMISE-1)[J]. Cephalagia, 2020, 40:241-254.
[21] Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine:PROMISE-2[J]. Neurology, 2020, 94:e1365-1377.
[22] Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine:the EVOLVE-1 randomized clinical trial[J]. JAMA Neurol, 2018, 75:1080-1088.
[23] Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine:results of the EVOLVE-2 phase 3 randomized controlled clinical trial[J]. Cephalalgia, 2018, 38:1442-1454. DI, Selzler KJ,
[24] Detke HC, Goadsby PJ, Wang S, Friedman Aurora SK. Galcanezumab in chronic migraine:the randomized, double-blind, placebo-controlled REGAIN study[J]. Neurology, 2018, 91:e2211-2221.
[25] Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of fremanezumab compared with placebo for prevention of episodic migraine:a randomized clinical trial[J]. JAMA, 2018, 319:1999-2008.
[26] Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the preventive treatment of chronic migraine[J]. N Engl J Med, 2017, 377:2113-2122.
[27] Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A controlled trial of erenumab for episodic migraine[J]. N Engl J Med, 2017, 377:2123-2132.
[28] Caronna E, Starling AJ. Update on calcitonin gene-related peptide antagonism in the treatment of migraine[J]. Neurol Clin, 2021, 39:1-19.
[29] Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW. Long-term safety, tolerability, and efficacy of fremanezumab in migraine:a randomized study[J]. Neurology, 2020, 95:e2487-2499.
[30] Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S, Smith J, Schaeffler B. Eptinezumab for the prevention of episodic migraine:sustained effect through 1 year of treatment in the PROMISE-1 study[J]. Clin Ther, 2020, 42:2254-2265.e3.
[31] Ashina M, Goadsby PJ, Reuter U, Silberstein Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD. Long-term efficacy and safety of erenumab in migraine prevention:results from a 5-year, open-label treatment phase of a randomized clinical trial[J]. Eur J Neurol, 2021, 28:1716-1725.
[32] Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache:subgroup analysis of PROMISE-2[J].Headache, 2021, 61:125-136.
[33] Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM. Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression:a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies[J]. Headache, 2020, 60:2202-2219. Tockhorn-Heidenreich A, Sexson M,
[34] Ruff DD, Ford JH, Govindan S, Pearlman EM, Wang SJ, Khan A, Aurora SK. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure[J]. Cephalalgia, 2019, 39:931-944. U, Boudreau G,
[35] Ashina M, Tepper S, Brandes JL, Reuter Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure:a subgroup analysis of a randomized, double-blind, placebo-controlled study[J]. Cephalalgia, 2018, 38:1611-1621.
[36] Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz CY, Grozinski-Wolff M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS):a randomised, double-blind, placebo-controlled, phase 3b trial[J]. Lancet, 2019, 394:1030-1040.
[37] Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. Correction to:European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention[J]. J Headache Pain, 2019, 20:58.
[38] Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine:a systematic review and meta-analysis[J]. J Headache Pain,2017, 18:42.

Please choose a citation manager

Content to export